Drug news
Epanova (Omthera) has better bioavailability than Lovaza
Omthera Pharmaceuticals has reported positive data showing that its prescription-grade omega-3 fatty acid candidate, Epanova, has better bioavailability than Lovaza (omega-3 ethyl esters) � the only FDA-approved omega-3 acid drug on the US market from GSK. The latest reported data from a 52-patient pharmacokinetic study showed that after 14 days of dosing and with a low fat diet, plasma EPA and DHA levels were 5.8 fold higher in patients treated with Epanova compared with those receiving Lovaza(Omacor in Europe). Additionally, Epanova increased steady state plasma levels of EPA plus DHA by 448%, compared to 90% for Lovaza. Omthera plans to file at the FDA this year based on the pivotal Phase III EVOLVE trial, from which top-line results are expected in the first half of 2012.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins